icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
Ira M. Jacobson1, Tarik Asselah2, Ronald Nahass3, Bal R. Bhandari4, Albert Tran5, Robert H. Hyland6, Luisa M. Stamm6, Hadas Dvory-Sobol6, Yanni Zhu6, Diana M. Brainard6, G. Mani Subramanian6, John G. McHutchison6, Stephen Shafran7, Mitchell Davis8, Catherine A. Stedman9, Eric Lawitz10, Edward J. Gane11 1. Mount Sinai Beth Israel, New York, NY; 2. H˘pital Beaujon, AP-HP, INSERM UMR 1149, UniversitÚ Paris Diderot, Clichy, France; 3. Infectious Disease Care, Hillsborough, NJ; 4. Gastroenterology & Nutritional Medical Services, Bastrop, LA; 5. Centre Hospitalier Universitaire de Nice, Nice, France; 6. Gilead Sciences, Inc., Foster City, CA; 7. University of Alberta, Edmonton, Alberta, Canada; 8. Digestive Care-South Florida Center of Gastroenterology, Wellington, FL; 9. Christchurch Hospital, Christchurch, New Zealand; 10. Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 11. Auckland Clinical Studies, Auckland, New Zealand

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6

HCV7